Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared a post on LinkedIn:
“Continuing on the theme of reflecting on the recent ESMO meeting, I am happy to provide details of the MSD-sponsored ESMO 2025 Industry Satellite Symposium that I participated in on 18th October 2025. It was a full house with excellent audience engagement and participation.
The main topic of discussion was the role of immunotherapy in the management of patients with locally-advanced, operable head and neck cancer. The meeting was superbly chaired by Hisham Mehanna and included excellent overviews of the recently published data from the practice-changing Keynote-689 study (by Ravindra Uppaluri) and the challenges inherent in assessing PD-L1 status in patients with head and neck cancer (by Cecile Badoual).
Alongside Robert Haddad, I had the pleasure of discussing with the other panel members the implications of the data and the opportunities for reshaping clinical practice. In particular, we focused on changes to current workflows as we introduce peri-operative pembrolizumab as a new standard-of-care therapy.
At the end of the session, we were delighted to share the platform with so many of the members of the MSD team who have been instrumental in delivering this ground-breaking study.
The session was recorded and I hope those who were unable to be there can catch up on its key messages on the ESMO 2025 platform.”
More posts featuring Kevin Harrington on OncoDaily.
